Immunotherapy for Infectious Diseases

Recommendations

Info

Cellular Immunology Principles 37 159:1560-1565. 55. Cher DJ, Mosmann TR. Two types of murine helper cell clone. II. Delayed-type hypersensitivity is mediated by T H1 clones. J Immunol 1987; 138:3688–3694. 56. Fong TA, Mosmann TR. The role of IFN-gamma in delayed-type hypersensitivity mediated by Th1 clones. J Immunol 1989; 143:2887–2893. 57. DeKruyff RH, Ju ST, Hunt AJ, Mosmann TR, Umetsu DT. Induction of antigen-specific antibody responses in primed and unprimed B cells. Functional heterogeneity among Th1 and Th2 T-cell clones. J Immunol 1989; 142:2575–2582. 58. Croft M, Swain SL. B cell response to T helper cell subsets: II. Both the stage of T cell differentiation and the cytokines secreted determine the extent and nature of helper activity. J Immunol 1991; 147:3679–3689. 59. Fiorentino DF, Zlotnik A, Vieira P, et al. Il-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991; 146:3444–3451. 60. Yamamura M, Uyemura K, Deans RJ, et al. Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Science 1991; 254:277–279. 61. Henderson GS, Conray JT, Summar M, McCurley TL, Colley DG. In vivo molecular analysis of lymphokines involved in the murine immune response during Schistosoma mansoni infection. I. Il-4 mRNA, not IL-2 mRNA, is abundant in the granulomatous livers, mesenteric lymph nodes, and spleens of infected mice. J Immunol 1991; 147:992–997. 62. Holaday BJ, Sadick MD, Wang Z-E, et al. Reconstitution of Leishmania immunity in severe combined immunodeficient mice using Th1- and Th2-like cell lines. J Immunol 1991; 147:1653–1658. 63. Salgame P, Abrams JS, Clayberger C, et al. Differing lymphokine profiles of functional subsets of human CD4 and CD8 T-cell clones. Science 1991; 254:279–282. 64. Salgame P, Convit J, Bloom BR. Immunological suppression by human CD8 � T cells is receptor dependent and HLA-DQ restricted. Proc Natl Acad Sci USA 1991; 88:2598–2602. 65. Sadick MD, Locksley RM, Tubbs C, Raff HV. Murine cutaneous leishmaniasis: resistance correlates with the capacity to generate interferon-gamma in response to Leishmania antigens in vitro. J Immunol 1986; 136:655–661. 66. Heinzel FP, Sadick MD, Holaday BJ, Coffman RL, Locksley RM. Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence <strong>for</strong> expansion of distinct helper T cell subsets. J Exp Med 1989; 169:59–72. 67. Locksley RM, Heinzel FP, Holaday BJ, Mutha SS, Reiner SL, Sadick MD. Induction of Th1 and Th2 CD4� subsets during murine Leishmania major infection. Res Immunol 1991; 142:28–32. 68. Coffman RL, Varkila K, Scott P, Chatelain R. Role of cytokines in the differentiation of CD4 � T-cell subsets in vivo. Immunol Rev 1991; 123:189–207. 69. Kelso A. Th1 and Th2 subsets: paradigms lost? Immunol Today 1995; 16:374–379. 70. Miller A, Lider O, Roberts AB, Sporn MB, Weiner HL. Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of trans<strong>for</strong>ming growth factor � after antigen-triggering. Proc Natl Acad Sci USA 1992; 89:421–425. 71. Chen Y, Kuchroo VK, Inobe J, Hafler DA, Weiner HL. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 1994; 265:1237–1240. 72. Groux H, O’Garra A, Bigler M, et al. A CD4� T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997; 389:737–742. 73. Modlin RL, Kato H, Mehra V, et al. Genetically restricted suppressor T-cell clones derived from lepromatous leprosy lesions. Nature 1986; 322:459–461. 74. Bloom BR, Mehra V, Melancon Kaplan J, et al. Mechanisms of immunological unrespon-
38 Bucy and Goepfert siveness in the spectra of leprosy and leishmaniasis. Adv Exp Med Biol 1988; 239:263–278. 75. Guler ML, Gorham JD, Hsieh C-S, et al. Genetic susceptibility to Leishmania: IL-12 responsiveness in T H1 cell development. Science 1996; 271:984–990. 76. Clerici M, Shearer GM. A TH1 → TH2 switch is a critical step in the etiology of HIV infection. Immunol Today 1993; 14:107–111. 77. Douek DC, McFarland RD, Keiser PH, et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 1998; 396:690–695. 78. Sprent J, Tough D. HIV results in the frame. CD4� cell turnover. Nature 1995; 375:194. 79. Mosier D. CD4� cell turnover. Nature 1995; 375:193–194. 80. Bucy RP, Hockett RD, Derdeyn CA, et al. Initial increase in blood CD4� lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J Clin Invest 1999; 103:1391–1398.
Page 1 and 2: Immunotherapy for Infectious Diseas
Page 3 and 4: In f e c t i o u s . D i s e a s e
Page 5 and 6: © 2002 Humana Press Inc. 999 River
Page 7 and 8: vi Preface I am grateful to all of
Page 9 and 10: viii Contents 11 Passive Immunother
Page 11 and 12: x Contributors BARBARA G. MATTHEWS,
Page 14 and 15: From: Immunotherapy for Infectious
Page 16 and 17: Humoral Immunity 5 Fig. 1. Humoral
Page 18 and 19: Humoral Immunity 7 Table 1 Properti
Page 20 and 21: Humoral Immunity 9 minal complement
Page 22 and 23: Humoral Immunity 11 ficity. In ligh
Page 24 and 25: Humoral Immunity 13 Fig. 7. VDJ joi
Page 26 and 27: Humoral Immunity 15 Fig. 9. Messeng
Page 28 and 29: Humoral Immunity 17 In contrast to
Page 30 and 31: Humoral Immunity 19 advantage to tr
Page 32 and 33: Humoral Immunity 21 32. Allman DM,
Page 34 and 35: Some Basic Cellular Immunology Prin
Page 36 and 37: Cellular Immunology Principles 25 i
Page 38 and 39: Cellular Immunology Principles 27 s
Page 40 and 41: Cellular Immunology Principles 29 d
Page 42 and 43: Cellular Immunology Principles 31 f
Page 44 and 45: Cellular Immunology Principles 33 F
Page 46 and 47: Cellular Immunology Principles 35 R
Page 50 and 51: INTRODUCTION Immune Defense at Muco
Page 52 and 53: Immune Defense at Mucosal Surfaces
Page 72: II Molecular Basis for Immunotherap
Page 75 and 76: 64 Kunert and Katinger IMMUNOGLOBUL
Page 77 and 78: 66 Fig. 2. Monomeric, dimeric, and
Page 79 and 80: 68 Kunert and Katinger Fig. 4. Humo
Page 81 and 82: 70 Kunert and Katinger remove prote
Page 83 and 84: 72 Kunert and Katinger Fig. 6. Diff
Page 85 and 86: 74 Kunert and Katinger persons of a
Page 87 and 88: 76 Kunert and Katinger that so-call
Page 89 and 90: 78 Kunert and Katinger whereas sele
Page 91 and 92: 80 Kunert and Katinger Different pr
Page 93 and 94: 82 Kunert and Katinger HUMAN/MOUSE
Page 95 and 96: 84 Kunert and Katinger are expresse
Page 97 and 98: 86 Kunert and Katinger missing meta
Page 99 and 100:
88 Kunert and Katinger Fig. 8. Sche
Page 101 and 102:
90 Kunert and Katinger include a se
Page 103 and 104:
92 Kunert and Katinger 32. Lee S, e
Page 105 and 106:
94 Kunert and Katinger 72. Abbs IC,
Page 107 and 108:
96 Kunert and Katinger 117. Wright
Page 110 and 111:
From: Immunotherapy for Infectious
Page 112 and 113:
Dendritic Cells 101 several organis
Page 114 and 115:
Dendritic Cells 103 tion that infec
Page 116 and 117:
Dendritic Cells 105 chaperones such
Page 118 and 119:
Dendritic Cells 107 CD8� CTLs, th
Page 120 and 121:
Dendritic Cells 109 complete tumor
Page 122 and 123:
Dendritic Cells 111 19. Holland SM,
Page 124 and 125:
Dendritic Cells 113 mouse pneumonit
Page 126 and 127:
Dendritic Cells 115 dendritic cells
Page 128 and 129:
INTRODUCTION Cytokines, Cytokine An
Page 130 and 131:
Cytokines, Cytokine Antagonists, an
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Principles of Vaccine Development F
Page 142 and 143:
Principles of Vaccine Development 1
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158:
Page 162 and 163:
INTRODUCTION Immunopathogenesis of
Page 164 and 165:
Immunopathogenesis of HIV Disease 1
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
Page 172:
Page 175 and 176:
164 Connick counts ranged from 73 t
Page 177 and 178:
166 Connick retinitis in an individ
Page 179 and 180:
168 Connick A novel method of ident
Page 181 and 182:
170 Connick occurs quite early in i
Page 183 and 184:
172 Connick 2. Delta Coordinating C
Page 185 and 186:
174 Connick 39. Hurni MA, Bohlen L,
Page 187 and 188:
176 Connick 76. Dolan M.J., Clerici
Page 189 and 190:
178 Connick 114. Komanduri KV, Visw
Page 192 and 193:
Page 194 and 195:
Active Immunization for HIV Infecti
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
Page 208:
Page 211 and 212:
200 Jacobson changes of gp120 alter
Page 213 and 214:
202 Jacobson is reduced (54,55). A
Page 215 and 216:
204 Jacobson Table 2 Potential Prot
Page 217 and 218:
206 Jacobson from the SIV/17E-Cl-in
Page 219 and 220:
208 Jacobson Several groups have de
Page 221 and 222:
210 Jacobson HUMAN STUDIES Polyclon
Page 223 and 224:
212 Jacobson clinical isolates, whi
Page 225 and 226:
214 Jacobson 22. Beasley RP, Hwang
Page 227 and 228:
216 Jacobson 59. Yoshiyama H, Mo H,
Page 229 and 230:
218 Jacobson 95. Prince AM, Reesink
Page 231 and 232:
220 Jacobson 133. Stiehm ER, Lamber
Page 233 and 234:
222 Kilby and Bucy Although clinica
Page 235 and 236:
224 Kilby and Bucy can infect human
Page 237 and 238:
226 Kilby and Bucy the proinflammat
Page 239 and 240:
228 Kilby and Bucy CD3/CD28, and th
Page 241 and 242:
230 Kilby and Bucy of viral replica
Page 243 and 244:
232 Kilby and Bucy 21. Cao Y, Qin L
Page 245 and 246:
234 Kilby and Bucy 64. Pantaleo G,
Page 247 and 248:
236 Kilby and Bucy 101. Clements-Ma
Page 249 and 250:
238 Dornburg and Pomerantz cells (5
Page 251 and 252:
240 Dornburg and Pomerantz Fig. 2.
Page 253 and 254:
242 Dornburg and Pomerantz domains
Page 255 and 256:
244 Dornburg and Pomerantz GENETIC
Page 257 and 258:
246 Dornburg and Pomerantz Fig. 5.
Page 259 and 260:
248 Dornburg and Pomerantz 6. Balti
Page 262 and 263:
Page 264 and 265:
Viral Infections Other than HIV 253
Page 266 and 267:
Page 268 and 269:
Page 270 and 271:
Page 272 and 273:
Virus-Associated Malignancies 261 c
Page 274 and 275:
Virus-Associated Malignancies 263 o
Page 276 and 277:
Virus-Associated Malignancies 265 I
Page 278 and 279:
Virus-Associated Malignancies 267 R
Page 280 and 281:
Virus-Associated Malignancies 269 T
Page 282 and 283:
Virus-Associated Malignancies 271 1
Page 284 and 285:
Virus-Associated Malignancies 273 5
Page 286 and 287:
Page 288 and 289:
Bacterial Infections and Sepsis 277
Page 290 and 291:
Page 292:
Page 295 and 296:
284 Wallis and Johnson replication
Page 297 and 298:
286 Wallis and Johnson Several stud
Page 299 and 300:
288 Wallis and Johnson monocytes, a
Page 301 and 302:
290 Wallis and Johnson peripheral b
Page 303 and 304:
292 Wallis and Johnson (A. Hise and
Page 305 and 306:
294 Wallis and Johnson infections,
Page 307 and 308:
296 Wallis and Johnson 37. Boom WH.
Page 309 and 310:
298 Wallis and Johnson 77. Ellner J
Page 311 and 312:
300 Wallis and Johnson 113. Raad I,
Page 313 and 314:
302 Wallis and Johnson 154. Anonymo
Page 315 and 316:
304 Table 1 Major Fungal Infections
Page 317 and 318:
306 Casadevall species suggest that
Page 319 and 320:
308 Casadevall transfusions from G-
Page 321 and 322:
310 Casadevall Table 3 Augmentation
Page 323 and 324:
312 Casadevall There has been some
Page 325 and 326:
314 Casadevall effective in achievi
Page 327 and 328:
316 Casadevall CONCLUSION AND FUTUR
Page 329 and 330:
318 Casadevall 16. Boutati EI, Anai
Page 331 and 332:
320 Casadevall 52. Gallin JI, Malec
Page 333 and 334:
322 Casadevall 91. Kowanko IC, Ferr
Page 335 and 336:
324 Index Blastomycosis, see Fungal
Page 337 and 338:
326 Index C-type retrovirus vectors
Page 339 and 340:
328 Index K Klebsiella, intravenous
Page 341 and 342:
330 Index Vaccine Recombinant vecto
Page 343:
Infectious Disease IMMUNOTHERAPY FO
show all

Immunotherapy for Infectious Diseases

Create successful ePaper yourself

Delete template?

Save as template?